Candel Therapeutics (CADL) Announces Third Quarter 2025 Financial Earnings Results And Recent Corporate Highlights

Candel Therapeutics, Inc. (CADL) today announced its financial results for the most recent quarter, revealing a diluted earnings per share of -$0.21, which fell short of analysts’ expectations by $0.02481. Despite the earnings miss, the company reported a revenue of $953,000, significantly surpassing revenue estimates. This positive revenue performance highlights Candel’s ongoing efforts to drive growth in a competitive market.

Key Highlights:

• Presented new subgroup analyses from the phase 3 clinical trial of CAN-2409 in localized prostate cancer, showing improved disease-free survival.
• Plans to initiate a pivotal phase 3 clinical trial of CAN-2409 in metastatic non-small cell lung cancer (NSCLC) in Q2 2026.
• Reported encouraging survival data from the phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma.
• A manuscript detailing the tissue response to CAN-3110 was published in Science Translational Medicine.
• Plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.
• Secured a $130 million term loan facility to support clinical trials and operations.
• Cash and cash equivalents stood at $87.0 million as of September 30, 2025.

Candel Therapeutics, a clinical-stage biopharmaceutical company, reported significant progress in its clinical pipeline during the third quarter of 2025. CEO Paul Peter Tak highlighted the positive subgroup analyses from the phase 3 trial of CAN-2409 in localized prostate cancer, which demonstrated improved disease-free survival independent of radiation therapy modality. The company is also preparing to initiate a pivotal phase 3 trial for CAN-2409 in patients with metastatic NSCLC by Q2 2026, following a positive end-of-phase 2 meeting with the FDA. Additionally, Candel is advancing its research on CAN-3110, with promising survival data reported for patients with recurrent high-grade glioma.

Financially, Candel secured a $130 million term loan facility, enhancing its cash position to support ongoing and future clinical trials. The company expects its current cash reserves, along with the loan proceeds, to fund operations into Q1 2027. With plans for a BLA submission for CAN-2409 in prostate cancer by the end of 2026, Candel is strategically positioned to advance its innovative immunotherapy programs aimed at treating various cancers.

Candel Therapeutics, Inc. (CADL) has experienced a notable decline in its stock price over the past month, dropping by 20.52%, which raises concerns among investors about the company’s short-term performance. Despite this recent downturn, the stock has shown resilience over the past year, with a 10.07% increase, suggesting potential for recovery. The company’s price-to-earnings ratio stands at a negative 7.18, indicating that it is currently operating at a loss, which could deter some investors. However, Candel’s impressive revenue growth over the past two years, with a compound annual growth rate (CAGR) of 288.23%, highlights its strong market potential and ability to scale. Additionally, a return on invested capital of 1.41 suggests that the company is beginning to generate some returns on its investments, albeit modestly. As the market continues to react to these financial metrics, investors will be keenly watching for signs of stabilization and growth in Candel’s performance. Overall, while the recent price changes may be disheartening, the underlying fundamentals present a mixed but intriguing picture for CADL’s future.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.